Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas

In the LIBERTY 1 and LIBERTY 2 placebo-controlled trials, once-daily relugolix combination therapy reduced menstrual blood loss volume and pain in women with heavy menstrual bleeding associated with uterine leiomyomas and was well tolerated, with preservation of bone mineral density (BMD) through 24...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hendy, Ayman, Lukes, Andrea S., Poindexter, Alfred N., Venturella, Roberta, Villarroel, Claudio, McKain, Laura, Li, Yulan, Wagman, Rachel B., Stewart, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Contents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665945/
https://www.ncbi.nlm.nih.gov/pubmed/36357960
http://dx.doi.org/10.1097/AOG.0000000000004988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665945/
https://www.ncbi.nlm.nih.gov/pubmed/36357960
http://dx.doi.org/10.1097/AOG.0000000000004988

Ejemplares similares